Oxford Gene Technology (OGT) offers the CytoSure Hematological Cancer +SNP array, which is optimized for the study of the hematological malignancies, chronic lymphocytic leukemia and multiple myeloma, as well as myeloproliferative neoplasms and myelodysplastic syndromes. The new array offers confident detection of both copy number variation (CNV) and loss of heterozygosity (LOH) on a single chip for these diseases. This is achieved by utilizing OGT’s novel array design, which combines long oligo array comparative genomic hybridization (aCGH) probes for CNV detection with fully validated single nucleotide polymorphism (SNP) content for identifying LOH.
The probes on the array have been optimized to target regions known to be important predictors of disease progression and patient prognosis in hematological cancers, while providing good backbone coverage. These features facilitate the rapid, reliable identification of key genomic aberrations, while the complimentary, industry-leading CytoSure Interpret Software allows intuitive, single-click data analysis. Using the array, researchers can move quickly and assuredly from processing their samples to generating relevant biological insight.
The CytoSure Haematological Cancer +SNP array offers reliable and accurate aCGH and LOH detection on a single array by utilizing a unique SNP probe design. Analysis is carried out using an intensity-based comparison between the two SNP alleles, meaning that no changes to the standard aCGH protocol are required and any reference sample can be used. This allows the two tests to operate effectively on the same array. In addition, CytoSure arrays utilise 60-mer oligonucleotide probes, which have been shown to offer higher signal-to-noise ratios and increased specificity and sensitivity, providing the highest data quality possible. For optimum performance, the array can be combined with the CytoSure Genomic DNA Labelling Kit, which offers high signal intensities enabling easier allele discrimination.
